<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VUSIONÂ - miconazole nitrate, zinc oxide and petrolatumÂ ointmentÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VUSION Ointment safely and effectively. See full prescribing information for VUSION Ointment.

VUSIONÂ® (miconazole nitrate, zinc oxide, and white petrolatum) Ointment, for topical use only

Initial U.S. Approval: 2006</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul>
<li>VUSION OintmentÂ  is indicated for adjunctive treatment of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> 
when complicated by documented <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (microscopic evidence of pseudohyphae 
and /or budding yeast) in immunocompetent pediatric patients 4 weeks and older. 
(<span class="Underline"><a href="#i4i_indications_id_7f59d836-969e-4d56-89be-7e7a61ae00e2">1</a></span>)</li>
<li>VUSION Ointment should not be used as a substitute for frequent diaper 
changes. (<span class="Underline"><a href="#i4i_indications_id_7f59d836-969e-4d56-89be-7e7a61ae00e2">1</a></span>)</li>
<li>VUSION Ointment should not be used to prevent the occurrence of diaper 
<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, since preventative use may result in the development of drug 
resistance. (<span class="Underline"><a href="#i4i_indications_id_7f59d836-969e-4d56-89be-7e7a61ae00e2">1</a></span>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>VUSION Ointment is for topical use only. VUSION Ointment is not for oral, 
ophthalmic, or intravaginal use. (<span class="Underline"><a href="#i4i_dosage_admin_id_150bdfe0-f448-4528-a928-b8d3a7e0a757">2</a></span>)</li>
<li>VUSION Ointment should be applied as a thin layer to the affected area at 
each diaper change for 7 days. (<span class="Underline"><a href="#i4i_dosage_admin_id_150bdfe0-f448-4528-a928-b8d3a7e0a757">2</a></span>)</li>
<li>VUSION Ointment should be used as part of a treatment regimen that includes 
gentle cleansing of the diaper area and frequent diaper changes. (<span class="Underline"><a href="#i4i_dosage_admin_id_150bdfe0-f448-4528-a928-b8d3a7e0a757">2</a></span>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Ointment with 0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white 
petrolatum. (<span class="Underline"><a href="#section-"> 3</a></span>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>None</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul><li>If irritation occurs or if the disease worsens, discontinue use of the 
medication, and contact the health care provider. (<span class="Underline"><a href="#i4i_warnings_precautions_id_2b33313d-2d01-4de9-979b-8799e3b9a8ff">5</a></span>)</li></ul>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact 
<span class="Bold">Stiefel Laboratories, Inc. at 1-866-440-5508</span> or FDA at 
1-800-FDA-1088 or <a href="http://%0A%09%09%09%09%09%09%09#invalid_link%0A%09%09%09%09%09%09">www.fda.gov/medwatch</a></span>. </p>
<br>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Indication</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-10.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage Conditions</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1 Indication</h2>
<p class="First">VUSION Ointment is indicated for the adjunctive treatment of 
diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> only when complicated by documented <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (microscopic 
evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric 
patients 4 weeks and older. A positive fungal culture for <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans </span>is not adequate evidence of candidal 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> since colonization with <span class="Italics">C. albicans</span> can 
result in a positive culture. The presence of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidal infection</span> should be 
established by microscopic evaluation prior to initiating treatment.</p>
<p>VUSION should be used as part of a treatment regimen that includes measures 
directed at the underlying diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, including gentle cleansing of the 
diaper area and frequent diaper changes.</p>
<p><span class="Bold">VUSION should not be used as a substitute for frequent 
diaper changes. VUSION should not be used to prevent the occurrence of diaper 
<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, since preventative use may result in the development of drug 
resistance.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>1.2 Limitations of Use</h2>
<p class="First"></p>
<p>The safety and efficacy of VUSION have not been demonstrated in 
immunocompromised patients, or in infants less than 4 weeks of age (premature or 
term).</p>
<p>The safety and efficacy of VUSION have not been evaluated in <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinent</span> 
adult patients. <span class="Bold"><span class="Underline">VUSION should not be used 
to prevent the occurrence of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, such as in an adult 
institutional setting, since preventative use may result in the development of 
<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">VUSION is not for oral, ophthalmic, or intravaginal use. </p>
<p>Before applying VUSION, gently cleanse the skin with lukewarm water and pat 
dry with a soft towel. Avoid using any scented soaps, shampoos, or lotions on 
the diaper area.</p>
<p>Apply VUSION to the affected area at each diaper change for 7 days. Continue 
treatment for the full 7 days, even if there is improvement. The safety of 
VUSION when used for longer than 7 days is not known. Do not use VUSION for 
longer than 7 days. If symptoms have not improved by day 7, see your health care 
provider.</p>
<p>Gently apply a thin layer of VUSION to the diaper area with the fingertips. 
Do not rub VUSION into the skin as this may cause additional irritation. 
Thoroughly wash hands after applying VUSION.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">White ointment containing 0.25% miconazole nitrate, 15% zinc 
oxide, and 81.35% white petrolatum.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">If irritation occurs or if the disease worsens, discontinue use 
of the medication, and contact the health care provider.</p>
<p>The safety and efficacy of VUSION have not been evaluated in <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinent</span> 
adult patients. <span class="Bold"><span class="Underline">VUSION should not be used 
to prevent the occurrence of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, such as in an adult 
institutional setting, since preventative use may result in the development of 
<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>.</span></span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying 
conditions, adverse reaction rate observed in the clinical trials of a drug 
cannot be directly compared to rates in the clinical trials of another drug and 
may not reflect the rates observed in clinical practice.</p>
<p>A total of 835 infants and young children were evaluated in the clinical 
development program. Of 418 subjects in the VUSION group, 58 (14%) reported one 
or more adverse events. Of 417 subjects in the zinc oxide/white petrolatum 
control group, 85 (20%) reported one or more adverse events. Adverse events that 
occurred at a rate of â‰¥ 1% for subjects who were treated with VUSION were 
approximately the same in type and frequency as for subjects who were treated 
with zinc oxide/white petrolatum ointment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post 
approval use of VUSION. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span>:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">GENERAL DISORDERS AND ADMINISTRATION SITE 
CONDITIONS:</span> <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, condition aggravated, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Italics">INJURY, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">POISONING</span> AND PROCEDURAL COMPLICATIONS:</span> 
accidental exposure</p>
<p><span class="Italics">SKIN AND SUBCUTANEOUS TISSUE DISORDERS:</span> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, 
<span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">dermatitis contact</span>, diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, skin 
<span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">exfoliation</span></p>
<p>Because these reactions are reported voluntarily from a population of 
uncertain size, it is not always possible to reliably estimate their frequency 
or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Drug-drug interaction studies were not conducted. Women who take 
a warfarin anticoagulant and use a miconazole intravaginal cream or suppository 
may be at risk for developing an increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, international 
normalized ratio (INR), and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The potential for this interaction between 
warfarin and VUSION is unknown.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<a href="http://"></a><span class="Bold">Pregnancy Category C</span><p class="First">There are no adequate and well-controlled studies of VUSION in 
pregnant women. Therefore, VUSION should be used during pregnancy only if the 
potential benefit justifies the potential risk to the fetus.</p>
<p>Miconazole nitrate administration has been shown to result in prolonged 
gestation and decreased numbers of live young in rats and in increased number of 
resorptions and decreased number of live young in rabbits at oral doses of 100 
mg/kg/day and 80 mg/kg/day, which are 28 and 45 times the maximum possible 
topical exposure of caregivers, respectively, assuming 100% absorption.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Safety and efficacy of VUSION have not been established in 
nursing mothers. It is not known if the active components of VUSION may be 
present in milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Efficacy was not demonstrated in infants less than 4 weeks of 
age. Safety and efficacy have not been established in very-low-birth-weight 
infants.</p>
<p>VUSION should not be used to prevent diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.</p>
<p>The safety of VUSION when used for longer than 7 days is not known. Do not 
use more than 7 days.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Safety and efficacy in a geriatric population have not been 
evaluated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VUSION contains the synthetic antifungal agent, miconazole 
nitrate (0.25%) USP, zinc oxide (15%) USP, and white petrolatum (81.35%) 
USP.</p>
<p>The chemical name of miconazole nitrate is 1-[2, 
4-dichloro-ÃŸ-{(2,4-dichlorobenzyl)oxy} phenethyl] imidazole mononitrate with 
empirical formula C<span class="Sub">18</span>H<span class="Sub">14</span>Cl<span class="Sub">4</span>N<span class="Sub">2</span>Oâ€¢HNO<span class="Sub">3</span> and 
molecular weight of 479.15. The structural formula of miconazole nitrate is as 
follows:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d8aaac5-3203-4ade-ae74-e2ea469dae18&amp;name=chemical%20structure.jpg"></p>
<p>The zinc oxide has an empirical formula of ZnO and a molecular weight of 
81.39.</p>
<p>The white petrolatum, which is obtained from petroleum and is wholly or 
nearly decolorized, is a purified mixture of semisolid saturated hydrocarbons 
having the general chemical formula C<span class="Sub">n</span>H<span class="Sub">2n+2</span>. The hydrocarbons consist mainly of branched and 
unbranched chains. White petrolatum contains butylated hydroxytoluene (BHT) as 
stabilizer.</p>
<p>Each gram of VUSION contains 2.5 mg of miconazole nitrate USP, 150 mg of zinc 
oxide USP, and 813.5 mg of white petrolatum USP containing butylated 
hydroxytoluene, trihydroxystearin, and Â Chemoderm<span class="Sup">Â®</span> 1001/B 
fragrance.<span class="Sup">1</span></p>
<p>VUSION is a smooth, uniform, white ointment.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The miconazole component of VUSION is an antifungal agent [see 
Clinical Pharmacology (<a href="#i4i_microbiology_id_046d97e2-25c6-41be-ba30-5d7bf24f31b6">12.4</a>)]. The 
mechanism of action of white petrolatum and zinc oxide for the adjunctive 
treatment of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The human pharmacodynamics of Vusion is unknown [see Clinical 
Pharmacology (<a href="#i4i_microbiology_id_046d97e2-25c6-41be-ba30-5d7bf24f31b6">12.4</a>) for 
fungal pharmacodynamics].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The topical absorption of miconazole from VUSION was studied in 
immunocompetent male and female infants and children (n=17) with diaper 
<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> complicated by documented <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (microscopic evidence of 
pseudohyphae and/or budding yeast) ranging in age from 1 month to 21 months. 
After multiple daily applications to the affected area at every diaper change 
(approximately 5-12 times per day) for 7 days, the plasma concentrations of 
miconazole were below the lower limit of quantitation (LOQ) of 0.5 ng/mL in 15 
out of 17 (88%) subjects. In the other 2 remaining subjects, the plasma 
concentrations of miconazole were 0.57 and 0.58 ng/mL, respectively at a single 
timepoint (4 hours after the last application) on Day 7.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-10.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">The miconazole nitrate component in this product has been shown 
to have <span class="Italics">in vitro</span> activity against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span>, an organism that is associated with 
diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>. The activity of miconazole nitrate against <span class="Italics">C. albicans</span> is based on the inhibition of the ergosterol 
biosynthesis in the cell membrane. The accumulation of ergosterol precursors and 
toxic peroxides results in cytolysis of the cell. <span class="Italics">In 
vitro</span> minimal inhibitory concentration (MIC) test results for <span class="Italics">C. albicans</span> isolates obtained from treatment failures in 
Clinical Study 1 (<span class="Italics">see Clinical Studies (<a href="#i4i_clinical_studies_id_cb70a8d4-df93-40f2-be6a-4f39bd8b7ce7">14</a>)</span>) 
does not appear to indicate that resistance to miconazole nitrate was the reason 
for treatment failure. The clinical significance of the <span class="Italics">in 
vitro</span> activity of miconazole nitrate against <span class="Italics">C. 
albicans</span> in the setting of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> is unclear.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The carcinogenic potential of VUSION in animals has not been 
evaluated.</p>
<p>Miconazole nitrate was negative in a bacterial reverse mutation test, a 
chromosome aberration test in mice, and micronucleus assays in mice and 
rats.</p>
<p>Miconazole nitrate had no adverse effect on fertility in a study in rats at 
oral doses of up to 320 mg/kg/day, which is 89 times the maximum possible 
topical exposure of caregivers, assuming 100% absorption.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Study 1 was a double-blind, multicenter study in which VUSION was 
compared to the zinc oxide and white petrolatum combination treatment and 
included 236 infants and toddlers with diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, complicated by 
<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> as documented by KOH tests that demonstrated psuedohyphae and/or 
budding yeasts. Study medication was applied at every diaper change for 7 
days.</p>
<p>The primary endpoint was â€œOverall Cureâ€? and required that subjects be both 
clinically cured (total resolution of all signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and 
microbiologically cured (eradication of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>). Primary efficacy was 
assessed 1 week following the end of treatment, at Day 14.</p>
<p>Study results are shown in the following table.</p>
<a href="http://"></a><a name="id4affb65-0272-49c4-888d-bc21da64c809"></a><table border="1" width="254">
<col width="28%">
<col width="28%">
<col width="42%">
<tbody class="Headless">
<tr class="First"><td>Overall Cure at Day 
14</td></tr>
<tr>
<td><br></td>
<td>
<p class="First">VUSION</p>n=112</td>
<td>
<p class="First">Zinc Oxide/White Petrolatum</p>n=124</td>
</tr>
<tr class="Last">
<td><br></td>
<td>26 (23%) </td>
<td>12 (10%)</td>
</tr>
</tbody>
</table>
<p>Two additional studies provided supportive evidence of the clinical efficacy 
of VUSION in infants and toddlers with diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, some of whom cultured 
positive for<span class="Italics"> C. albicans</span>. However, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidal infection</span> 
was not documented in the culture-positive subjects, as microscopic testing 
(e.g. KOH) was not done. Therefore, the positive culture results may have 
reflected colonization rather than <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">VUSION is a smooth, uniform, white ointment supplied in an 
aluminum tube, as follows:</p>
<p>50g (NDC 54868-6246-0)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.2"></a><p></p>
<h2>16.2 Storage Conditions</h2>
<p class="First">Store at controlled room temperature between 20Â°C and 25Â°C (68Â°F 
and 77Â°F); with excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F).</p>
<p>Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling</span></p>
<p>Patients using VUSION should be informed about the following information:</p>
<ul>
<li>VUSION is to be used only for diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> that is complicated by 
documented <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (i.e. documented by microscopic testing).</li>
<li>VUSION should not be used as a substitute for frequent diaper changes.</li>
<li>VUSION should not be used to prevent diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.</li>
<li>VUSION should not be used long term.</li>
<li>VUSION should be used only as directed by the health care provider.</li>
<li>VUSION is for external use only. It is not for oral, ophthalmic, or 
intravaginal use.</li>
<li>Gently cleanse the diaper area with lukewarm water or a very mild soap and 
pat the area dry with a soft towel before applying VUSION.</li>
<li>Gently apply VUSION to the diaper area with the fingertips after each diaper 
change. Do not rub VUSION into the skin as this may cause additional 
irritation.</li>
<li>Thoroughly wash hands after applying VUSION.</li>
<li>Treatment should be continued for 7 days, even if there is improvement. Do 
not use VUSION for longer than 7 days. If symptoms have not improved by day 7, 
see your health care provider.</li>
<li>VUSION should not be used on children for whom it is not 
prescribed.</li>
</ul>
<p>VSN:2PI</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold"><br><br>VUSION<span class="Sup">Â®</span> (Vu-sion) 
Ointment</span></p>
<p><span class="Bold">(0.25% miconazole nitrate, 15% zinc oxide and 81.35% white 
petrolatum)</span></p>
<p><span class="Italics"><span class="Underline"><br><br>IMPORTANT: For Skin Use 
Only. Do not use in the mouth, eyes, or vagina.Â  </span></span></p>
<p>Read the Patient Information that comes with VUSION before you use it on your 
child. This leaflet does not take the place of talking to your health care 
provider about your childâ€™s medical condition or treatment. If you have any 
questions or if you are not sure about any of the information on VUSION, ask 
your health care provider, or pharmacist.</p>
<p><span class="Bold"><br>What is VUSION?</span></p>
<p>VUSION is a prescription skin medicine used to treat <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> that also 
has a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> in children who are at least 4 weeks old and who have a 
normal immune system. VUSION contains medicines that will help treat the yeast 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span>, <span class="Italics"><span class="Underline">but you 
must also change your childâ€™s diapers very often so that your child is not 
wearing a wet or soiled diaper.Â </span></span> Even if you use VUSION, <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> will not go away if you do not 
keep your childâ€™s diaper area clean and dry. </span></span>You should use water 
or a very mild cleanser to clean your childâ€™s diaper area. VUSION is not to be 
used to prevent <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> or to be used for more than 7 days.</p>
<p><span class="Italics"><span class="Underline">Your health care provider will need 
to do a special test to tell if your childâ€™s <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> also has a yeast 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Do not use VUSION on your childâ€™s <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> unless your health care 
provider tells you that there is also a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</span></span></p>
<p><span class="Bold"><br>Who should not use VUSION?</span></p>
<p>VUSION is not for treatment of all cases of <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span>. VUSION is only for 
<span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> that also has a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>. Most cases of <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> do not 
need the yeast medicine that is in VUSION because most cases of <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> do 
not also have a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</p>
<p><span class="Italics"><span class="Underline">Do not use VUSION on any other 
children or other family member.</span></span></p>
<p><span class="Italics"><span class="Underline">Do not use VUSION on your childâ€™s 
<span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> if they are allergic to anything in it.Â </span></span> See the end 
of this leaflet for a list of ingredients in VUSION.</p>
<p>Do not use on infants less than 4 weeks of age.</p>
<p>Do not use in infants or children who do not have a normal immune system.</p>
<p><span class="Bold"><br>How should I use VUSION on my child?</span></p>
<p>VUSION is applied to the skin on your childâ€™s diaper area at each diaper 
change for 7 days. </p>
<p>Apply VUSION for the full 7 days even if the <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> starts to go away. 
Call your childâ€™s health care provider if the <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> gets worse or does not 
go away with 7 days of treatment with VUSION. <span class="Italics"><span class="Underline">VUSION should not be used for more than 7 days.</span></span></p>
<p><span class="Bold"><br>To apply VUSION:</span></p>
<ul>
<li>Gently, clean the skin on your childâ€™s diaper area with warm (<span class="Italics"><span class="Underline">not hot</span></span>) water. You may also 
use a very mild soap. Pat the area dry with a soft towel.</li>
<li>Use your fingertips and gently apply a thin layer of VUSION to your childâ€™s 
diaper area at each diaper change. Do not rub VUSION into your childâ€™s skin. 
Rubbing the skin can cause more irritation.</li>
<li>Wash your hands after applying VUSION on your child.</li>
</ul>
<p><span class="Bold">VUSION is for skin use only.</span></p>
<p>Call your childâ€™s health care provider or poison control center right away if 
any VUSION is swallowed. Call your childâ€™s health care provider if VUSION gets 
in the eye.</p>
<p>Keep out of reach of children.</p>
<p><span class="Bold"><br>What other steps will help <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> go away?</span></p>
<ul>
<li>Check your childâ€™s diaper often. Change the diaper at the first sign of 
wetness.</li>
<li>Clean your childâ€™s diaper area after each diaper change. Gently wipe the 
diaper area from the front to back using warm <span class="Bold">(</span><span class="Italics"><span class="Underline">not hotÂ </span></span><span class="Bold">) 
</span>water. You may also use a mild soap. Rinse the diaper area well. Pat dry 
with a soft towel.</li>
<li>Keep the diaper area open to air when possible.</li>
<li>Even if you use VUSION, <span class="Italics"><span class="Underline">diaper 
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> will not go away if you do not keep your childâ€™s diaper area clean and 
dry.</span></span>
</li>
</ul>
<p><span class="Bold"><br>What are the possible side effects of VUSION?</span></p>
<p>VUSION may cause irritation. You should call your childâ€™s health care 
provider if irritation appears or if the <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> gets worse.</p>
<p><span class="Bold"><br>How should I store VUSION?</span></p>
<ul>
<li><span class="Italics"><span class="Underline">Keep VUSION out of the reach of 
children to avoid the risk of accidental ingestion.</span></span></li>
<li>Store VUSION at room temperature between 68Â°F to 77Â°F (20Â°C to 
25Â°C).</li>
</ul>
<p><span class="Bold">General information about VUSION</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in 
patient information leaflets.</p>
<p>Do not use VUSION for a condition for which it was not prescribed. Do not 
give VUSION to other children or family members, even if they have the same 
symptoms your child has. It may harm them.</p>
<p>This leaflet summarizes the most important information about VUSION. If you 
would like more information, talk to your childâ€™s health care provider. You can 
ask your childâ€™s health care provider or pharmacist for information about VUSION 
that is written for healthcare professionals.</p>
<p><span class="Italics"><span class="Underline">Side effects may be reported to 
Stiefel Laboratories, Inc. at 1-866-440-5508 or the FDA at 
1-800-FDA-1088.</span></span></p>
<p><span class="Bold"><br>What are the ingredients in VUSION?</span></p>
<p><span class="Italics"><span class="Underline">Active Ingredients:Â </span></span> 
miconazole nitrate, zinc oxide, and white petrolatum </p>
<p><span class="Italics"><span class="Underline">Inactive 
Ingredients:Â </span></span> trihydroxystearin, butylated hydroxyltoluene (BHT), 
and Chemoderm<span class="Sup">Â®</span> 1001/B fragrance</p>
<p><br>This Patient Information leaflet has been approved by the U.S. Food and 
Drug Administration.</p>
<p>The Patient Information leaflet was last revised: January 2010</p>
<p><br>VSN:2PIL</p>
<p><br><span class="Bold">Manufactured for:</span></p>
<p>Stiefel Laboratories, Inc.</p>
<p>Coral Gables, FL 33134 USA</p>
<p><br><span class="Bold">Manufactured by:</span></p>
<p>DSM Pharmaceuticals, Inc.</p>
<p>Greenville, NC 27834</p>
<p><br>VUSION, STIEFEL, and STIEFEL &amp; Design are registered trademarks of 
Stiefel Laboratories, Inc.</p>
<p><br><span class="Sup">1</span>ChemodermÂ  is a registered trademark of Firmenich 
Inc.</p>
<p><br>Â©2010 Stiefel Laboratories, Inc.</p>
<p><br>Revised March 2010</p>
<p>SAP#</p>
<p>P/N #</p>
<br><p><br></p>
<p><span class="Bold">Relabeling of "Additional" barcode label by;</span></p>
<p>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â Â Â  74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0145-0002-04</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d8aaac5-3203-4ade-ae74-e2ea469dae18&amp;name=6246.jpg"></p>
<p><span class="Bold">Vusion<span class="Sup">Â®</span></span></p>
<p>(miconazole nitrate 0.25% USP, zinc oxide 15% USP, white petrolatum 81.35% 
USP)</p>
<p><span class="Bold">Ointment</span></p>
<p><span class="Bold">50 grams</span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p>For topical use only </p>
<p><span class="Bold">Usual Dosage:</span> See package insert.</p>
<p><span class="Bold">Caution: Not for oral, ophthalmic, or intravaginal use. Keep 
out of reach of children. If seal is damaged or punctured, do not use, and 
return product to place of purchase.</span></p>
<p><span class="Bold">Description: </span>Each gram of VUSION<span class="Sup">Â®</span> Ointment contains 2.5 mg miconazole nitrate USP, 150 mg zinc 
oxide USP, and 813.5 mg white petrolatum USP containing butylated 
hydroxytoluene, trihydroxystearin, and Chemoderm<span class="Sup">Â®</span> 1001/B 
fragrance.</p>
<p>Store at 15<span class="Sup">o</span>C (77<span class="Sup">o</span>F); 
excursions permitted to 25<span class="Sup">o</span>C -30<span class="Sup">o</span>C 
(59<span class="Sup">o</span>F -86<span class="Sup">o</span>F).</p>
<p>See tube crimp for lot number and expiration date. </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VUSIONÂ 		
					</strong><br><span class="contentTableReg">miconazole nitrate, zinc oxide, white petrolatum ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6246(NDC:0145-0002)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MICONAZOLE NITRATE</strong> (MICONAZOLE) </td>
<td class="formItem">MICONAZOLE NITRATE</td>
<td class="formItem">2.5Â mg Â inÂ 1Â g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ZINC OXIDE</strong> (ZINC OXIDE) </td>
<td class="formItem">ZINC OXIDE</td>
<td class="formItem">150Â mg Â inÂ 1Â g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PETROLATUM</strong> (PETROLATUM) </td>
<td class="formItem">PETROLATUM</td>
<td class="formItem">813.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCOL STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6246-0</td>
<td class="formItem">50 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021026</td>
<td class="formItem">04/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dc77182b-f12d-4f92-a0c1-06cd63d6a68b</div>
<div>Set id: 8d8aaac5-3203-4ade-ae74-e2ea469dae18</div>
<div>Version: 1</div>
<div>Effective Time: 20110420</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
